论文部分内容阅读
目的分析G蛋白偶联受体30(GPR30)在卵巢癌发生发展中的变化情况。方法选取2013年3月—2015年3月新疆医科大学附属肿瘤医院妇外一科治疗的上皮性卵巢癌患者75例和良性上皮性卵巢肿瘤患者45例手术标本作为研究对象,另选取75例卵巢癌标本的癌旁组织作为对照组,检测组织标本中GPR30的表达。采用免疫荧光技术和流式分选技术检测GPR30在卵巢癌的亚细胞定位。通过免疫组化法检测GPR30在卵巢癌组织、良性上皮卵巢肿瘤组织、癌旁组织中的表达。患者出院后进行追踪随访,进一步分析GPR30与卵巢癌发生发展的关系。结果免疫荧光技术和流式分选技术显示GPR30在细胞核上的表达高于细胞质上的表达(90.13%vs.70.37%,χ~2=8.654,P<0.05);上皮性卵巢癌中GPR30的高表达率明显高于良性上皮卵巢肿瘤组织和癌旁组织(分别为80.0%、53.3%、32.0%,χ~2=35.065,P<0.01);不同组织类型的上皮性卵巢癌GPR30高表达率存在差异,且临床分期中,Ⅲ~Ⅳ期上皮性卵巢癌的GPR30高表达率高于Ⅰ~Ⅱ期(86.9%vs.50.0%,χ~2=7.514,P<0.01);GPR30的高表达率复发患者高于未复发患者(94.3%vs.45.5%,χ~2=20.266,P<0.01),死亡患者高于存活患者(95.2%vs.75.9%,χ~2=4.231,P<0.05)。结论卵巢癌的发生和发展可能与GPR30的参与有关,并且与卵巢癌的侵袭和转移存在相关性,因此GPR30可作为卵巢癌的诊断和恶性程度判断依据之一。
Objective To analyze the changes of G protein - coupled receptor 30 (GPR30) in the development of ovarian cancer. Methods From March 2013 to March 2015, 75 patients with epithelial ovarian cancer and 45 patients with benign epithelial ovarian tumors underwent gynecology and gynecology in Cancer Hospital Affiliated to Xinjiang Medical University were enrolled in this study. Another 75 ovarian cancer patients The paracancerous tissues of cancer specimens were used as a control group to detect the expression of GPR30 in the tissue specimens. Immunofluorescence and flow cytometry were used to detect subcellular localization of GPR30 in ovarian cancer. The expression of GPR30 in ovarian cancer tissues, benign epithelial ovarian tumor tissues and paracancerous tissues was detected by immunohistochemistry. Patients were followed up after discharge, further analysis of the relationship between GPR30 and the occurrence and development of ovarian cancer. Results The results of immunofluorescence and flow cytometry showed that the expression of GPR30 in nucleus was higher than that in cytoplasm (90.13% vs.70.37%, χ2 = 8.654, P <0.05). The high GPR30 in epithelial ovarian cancer The expression rate of GPR30 was significantly higher in benign epithelial ovarian cancer tissues and adjacent tissues (80.0%, 53.3%, 32.0%, χ ~ 2 = 35.065, respectively, P <0.01) (P <0.01). The high expression rate of GPR30 in stage Ⅲ ~ Ⅳ epithelial ovarian cancer was higher than that in stage Ⅰ ~ Ⅱ (86.9% vs. 50.0%, χ ~ 2 = 7.514, P <0.01) The patients with recurrence were higher than those without recurrence (94.3% vs.45.5%, χ ~ 2 = 20.266, P <0.01), and those who died were higher than survivors (95.2% vs.75.9%, χ ~ 2 = 4.231, . Conclusion The occurrence and development of ovarian cancer may be related to the involvement of GPR30 and the invasion and metastasis of ovarian cancer. Therefore, GPR30 may be used as a basis for the diagnosis and malignancy of ovarian cancer.